Eli Lilly Announces Retatrutide Results Surpassing Ozempic in Clinical Trials
LLY Lilly(Eli) & Co
$1415.55 -1.13%
View chart & analysis → - 1Retatrutide recorded higher A1C reduction and weight loss effects than Ozempic in clinical trials.
- 2Eli Lilly reached a market capitalization of $1.36 trillion, increasing its market value over the past decade.
- 3Zepbound recorded $228 million in sales in the third quarter, a 59% increase from the previous year.
So what's the key point?
Results show that Eli Lilly's new drug reduced blood sugar and body weight more effectively than the existing drug. This achievement has grown the company's value to $1.36 trillion.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.